Comparative Pharmacology
Head-to-head clinical analysis: DEXAMPEX versus DYANAVEL XR 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMPEX versus DYANAVEL XR 10.
DEXAMPEX vs DYANAVEL XR 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextroamphetamine is a central nervous system stimulant that increases extracellular dopamine and norepinephrine levels by blocking their reuptake and promoting release from presynaptic terminals.
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
5-10 mg orally once daily in the morning, maximum 20 mg/day.
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
None Documented
None Documented
Terminal elimination half-life 10–13 hours in adults (7–8 hours in children). Longer in alkaline urine (up to 20 hours) due to reduced renal tubular reabsorption.
12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing
Renal: ~90% as unchanged drug and metabolites (primarily deaminated metabolites); fecal/biliary <2%.
Renal (80-90% as unchanged drug); fecal (minor, 1-5%)
Category C
Category C
CNS Stimulant
CNS Stimulant